Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 TB31F in healthy malaria-naive adults
NL-OMON50099Phase 1Completed
- Sponsor
- Radboud University Medical Center
- Start
- Feb 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of TB31F in malaria (2 arms), sponsored by Radboud University Medical Center. Primary endpoints: Solicited local adverse events, Solicited general adverse events and 2 more. Started Feb 2020; status: completed.
02
Drugs
TB31F
03
Conditions
malaria
Beyond the preview
Go deeper on NL-OMON50099.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50099.